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AIM 
 
 
The aim of this study is to estimate the prevalence of electrolyte abnormality (sodium and  
calcium) in adults admitted with active tuberculosis in a tertiary hospital.  
 
 
OBJECTIVES 
 
PRIMARY OBJECTIVE 
 
1. To calculate the prevalence of hypo/hypernatremia and hypo/hypercalcemia.  
 
SECONDARY OBJECTIVES 
 
1. To assess the mechanism of hyponatremia 
2. To assess the relation between type of tuberculosis and electrolyte abnormality 
3. To assess outcome at discharge in relation to electrolyte abnormality 
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INTRODUCTION 
 
Tuberculosis is a communicable infectious disease, transmitted almost exclusively by 
cough aerosol, caused by the Mycobacterium tuberculosis complex, and characterised 
pathologically by necrotising granulomatous inflammation usually in the lung (~85% 
of cases), although almost any extrapulmonary site can be involved. 
 
Tuberculosis is one of the most common infection in India and is associated with high 
mortality. In India, an estimated 2.8 million people developed TB in 2015. Prevalence 
of tuberculosis in India is estimated to be about 250 (per 100000 population). 
Tuberculosis ranks above HIV/AIDS as one of the leading causes of death from an 
infectious disease, despite the fact that with timely diagnosis and correct treatment, 
most people who develop tuberculosis can be cured. Electrolyte abnormalities are 
associated with increased duration of hospitalization, mortality and morbidity in 
hospitalized patients. Previous studies have shown electrolyte abnormalities are quite 
common in tuberculosis.  There are no studies done in India estimating the prevalence 
of electrolyte abnormalities in hospitalized adult patients with active tuberculosis. The 
mechanism of these abnormalities has also not been studied. Knowledge of electrolyte 
abnormality seen in tuberculosis patients can result in early detection and treatment of 
these abnormalities, possibly shorten the hospital stay, morbidity and mortality 
associated with the disease. Hence, we intend to study and estimate the prevalence of 
dyselectrolytemia among tuberculosis patients. 
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LITERATURE REVIEW 
 
 
10.4 million new cases of tuberculosis were reported worldwide in 2015, out of which 
an estimated 5.9 million (56%) cases were among men, 3.5 million (34%) cases were 
among women and 1.0 million (10%) cases were among children. 1.2 million (11%) 
new tuberculosis cases were among people living with human immunodeficiency 
virus infection. In 2015, an estimated 1.4 million people succumbed to tuberculosis 
and an additional 0.4 million died from tuberculosis among people with human 
immunodeficiency virus infection.  More than 60% of these patients were in China, 
India, the Russian Federation, Pakistan, and South Africa. The absolute number of 
cases is highest in Asia, with India and China having the greatest burden of disease 
globally.  
 
Tuberculosis is one of the most common infection in India and is associated with high 
mortality.  Although mortality rate in tuberculosis decreased by 22% between 2000 
and 2015, tuberculosis remained as one of the top ten causes of death worldwide in 
2015. It ranked above HIV/AIDS as one of the leading causes of death from an 
infectious disease, despite the fact that with a timely diagnosis and correct treatment, 
most people who develop tuberculosis can be cured. In India, an estimated 2.8 million 
people developed TB in 2015. Incidence of tuberculosis in India is estimated to be 
about 217 (per 100000 population)(1). Mortality rate in India is 36 (per 100000 
population, excluding HIV + tuberculosis) and 2.8 (per 100000, only HIV + 
tuberculosis).  
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In a retrospective review published in 2014, mortality records of 249 culture-proven 
cases of tuberculosis diagnosed during 2003-2007, who died before completion of 
treatment in a tertiary hospital in Taiwan were analysed.  The mortality rate (all-cause) 
among tuberculosis patients was 12.4%, and this was mainly attributed to non-
tuberculosis-related causes (82.7%). Majority of non-tuberculosis related deaths were 
due to malignancy and secondary bacterial infection.  A sizeable proportion of deaths 
among tuberculosis patients was due to underlying comorbid conditions. Malignancy, 
cirrhosis of liver, renal failure, miliary and pneumonic radiographic patterns were 
main predictors of mortality in tuberculosis deaths(2).  
 
TUBERCULOSIS 
 
In 1882, Robert Koch discovered the causative agent of tuberculosis (TB), an airborne 
infectious disease caused by organisms of the Mycobacterium tuberculosis complex. 
tuberculosis continues to be a major cause of morbidity and mortality, primarily in 
low-income and middle-income countries(1).  
 
M. tuberculosis can cause disease throughout the body, despite being a primary 
pulmonary pathogen. Besides, tuberculosis can present as a dynamic spectrum, from 
asymptomatic infection to a life-threatening disease(3). From a clinical and public 
health point of view, patients with tuberculosis are pragmatically classified as having 
latent tuberculosis infection (LTBI), which is an asymptomatic and non-transmissible 
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state, or active tuberculosis disease, which is transmissible (in active pulmonary 
tuberculosis) and for which culture-based or molecular diagnostics can be used. 
Patients with active tuberculosis experience symptoms such as fever, fatigue, lack of 
appetite and weight loss, and those with pulmonary disease can have persistent cough 
and haemoptysis in advanced disease. However, some patients with active, culture-
positive disease may be asymptomatic and are best described as having subclinical 
tuberculosis(3). 
 
Standard tuberculosis treatment comprises four first-line antimicrobials: isoniazid, 
rifampicin, pyrazinamide and ethambutol. Resistance to all drugs can occur. 
Multidrug-resistant tuberculosis (MDR-TB) — defined as M. tuberculosis resistant to 
at least isoniazid and rifampicin — is a well-recognized entity that has been 
reported(1). Extensively drug resistant tuberculosis disease, which causes even more 
severe disease manifestations, is not only resistant to isoniazid and rifampicin but also 
to any fluoroquinolone and any of the three injectable second-line aminoglycosides. 
Diagnostic and therapeutic options vary for latent tuberculosis infection and 
active tuberculosis disease, and for drug-sensitive and drug-resistant tuberculosis. 
 
Among major known risk factors for tuberculosis, HIV infection is the strongest(4); 
HIV-positive cases account for 12% of all new active tuberculosis cases and 25% of 
all tuberculosis-related deaths. The majority (75%) of HIV associated active 
tuberculosis cases and deaths occur in Africa(5). A systematic review showed that 
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active tuberculosis was the leading cause of hospitalization among HIV-infected 
adults (18%) and children (10%)(6). As HIV-positive individuals make up only 0.5% 
of the world’s population, other risk factors are responsible for the remaining fraction 
of tuberculosis cases in the general population. An estimated 27% of tuberculosis 
cases worldwide are attributable to undernutrition and 22% to indoor air pollution(7). 
Other risk factors for tuberculosis include type 2 diabetes mellitus(8), excessive 
alcohol use(9) (both of which roughly triple the risk of TB) and smoking (which 
doubles the risk)(10). 
 
The natural history of tuberculosis is defined by its airborne route of transmission and 
the diversity of its clinical manifestations. M. tuberculosis is not highly infectious as 
compared with infectious agents such as measles virus and varicella zoster virus, an 
average infectious individual might infect 3–10 people per year, of whom only a 
minority will progress to active TB disease(11). However, among those with active 
tuberculosis, the average duration of infection — as inferred from the incidence to 
prevalence ratio — is >1 year in many high-burden settings(12). In the absence of 
treatment, approximately 50% of individuals who develop active tuberculosis will 
succumb to it(13). 
 
Epidemiology trends of tuberculosis reveal marked disparities. From 1900 to 1980, 
tuberculosis related deaths in western Europe and the United States fell by more than 
100-fold(14). Majority of this decline occurred before the discovery of effective anti-
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tuberculosis drugs. This decline was attributed to general improvements in hygiene 
and socioeconomic conditions. However, progress in most high-burden settings has 
been much slower. The current worldwide rate of decline in incidence is only about 
1.5% per year(1). More-rapid progress has been seen in certain areas; for example, 
China halved its prevalence of active tuberculosis disease and reduced tuberculosis-
related mortality by an estimated 80% over a period of 20 years (1990–2010)(15). By 
contrast, because of the effect of the HIV epidemic, the incidence of active 
tuberculosis increased during the same time period in Africa, primarily(1).  
 
Treatment for tuberculosis saved an estimated 43 million lives between 2000 and 
2014. The WHO estimates that over one-third of all individuals who develop active 
tuberculosis are never diagnosed or notified to public health authorities, based on the 
difference between estimated and notified cases — these ‘missing 3.6 million’ 
constitute a major challenge in ongoing efforts to control TB(1). 
 
Another major concern is the emergence of drug resistance, and its distribution is 
particularly heterogeneous. The prevalence of MDR-tuberculosis (globally) is 
estimated at 5% (3.5% in new cases of active TB disease and 20.5% in previously 
treated cases). The prevalence varies widely from approximately 1% in many 
countries in sub-Saharan  Africa, western Europe and north America to more than 
20% in areas of the former Soviet Union, such as Azerbaijan, Belarus, Kyrgyzstan and 
Moldova(16). Of concern in recent years has been the problem of drug resistant 
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tuberculosis in China (where one-quarter of all active tuberculosis cases are resistant 
to either isoniazid or rifampicin)(17) and India (which has witnessed the emergence of 
so-called totally drug-resistant strains)(18). Most cases of MDR-tuberculosis are 
estimated to reflect transmission rather than initial acquisition(19). Thus, a high 
priority for the response to drug-resistant tuberculosis is to identify and target 
‘hotspots’ of MDR-tuberculosis transmission(20). 
 
A complete understanding of how M. tuberculosis develops resistance has the 
potential to revolutionize tuberculosis care, so efforts to catalogue resistance-
associated mutations are ongoing, using epidemiologically representative strain 
collections coupled with patient outcome data(21). Genome sequencing and molecular 
platforms that detect mutations that confer drug resistance also need to be developed 
to support the introduction of new drug regimens for active tuberculosis(22).  
 
Current regimens are long, cumbersome and toxic. New medicines and universal 
regimens (that can be used in both drug sensitive tuberculosis and MDR-tuberculosis) 
are being studied to shorten duration, facilitate administration and enable safe use in 
people with comorbidities. However, the development pipeline remains very limited. 
Regimens that simplify and shorten latent tuberculosis treatment are also a priority, as 
any attempt to eradicate tuberculosis needs to address the huge pool of individuals 
with latent tuberculosis. 
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CASE DEFINITIONS 
 
A bacteriologically confirmed tuberculosis case has a biological specimen positive by 
smear microscopy, culture or world health organisation approved rapid diagnostic 
methods (such as Xpert MTB/RIF).  
 
A clinically diagnosed tuberculosis case is defined as one who does not fulfil 
bacteriological confirmation criteria, but has been diagnosed by a clinician or other 
medical practitioner as active tuberculosis and has been initiated on full course 
empirical tuberculosis treatment. This definition includes cases diagnosed based on 
radiographical abnormalities or suggestive histology and extrapulmonary cases without 
laboratory/microbiological confirmation.  
Pulmonary tuberculosis (PTB) refers to tuberculosis involving the lung parenchyma or 
the tracheobronchial tree which is confirmed bacteriologically or clinically diagnosed.   
 
When tuberculosis involves organs other than the lungs, which is confirmed 
bacteriologically or diagnosed clinically, it is classified as Extrapulmonary tuberculosis 
(EPTB).  Organs involved can be pleura, lymph nodes, abdomen, genitourinary tract, 
skin, joints and bones or meninges (23). 
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Disseminated tuberculosis refers to tuberculosis involving the blood stream, bone 
marrow, liver, or two or more non-contiguous sites, or miliary tuberculosis(24). 
 
PATHOGENESIS 
 
Transmission 
Tuberculosis transmission occurs when the organism is exhaled as an aerosol by the 
cough of an infected patient and inhaled into the alveoli of a new host.  
 
Outcomes after infection 
The human host serves as a natural reservoir for M. tuberculosis. Exposure to M 
tuberculosis infrequently leads to symptomatic disease. The ability of the organism to  
efficiently establish latent infection has enabled it to spread to nearly 30% of 
individuals worldwide.  
 
Latent tuberculosis 
Stimulation by Mycobacterium tuberculosis antigens results in a state of persistent 
immune response without evidence of clinically manifested active tuberculosis called 
Latent tuberculosis infection (LTBI). It is estimated that the lifetime risk of 
20 
 
reactivation for a person with documented latent tuberculosis infection is between 5 to 
10%.  
 
Development of disease is a function of the immunocompetency of the host. Although 
human immunodeficiency virus coinfection is the most notable cause for progression 
to active disease, there are other variables, such as uncontrolled diabetes mellitus, 
sepsis, renal failure, malnutrition, smoking, chemotherapy, organ transplantation, and 
long-term corticosteroid usage, that can potentially trigger reactivation of latent 
tuberculosis. 
 
Primary disease 
Out of the approximately 5 to 10 percent of infected individuals who eventually 
progress to develop active tuberculosis, approximately 50% will do so within the first 
two to three years following the infection. 
 
Primary pulmonary tuberculosis 
Primary pulmonary tuberculosis occurs immediately after infection with tuberculosis. 
It maybe asymptomatic or may present as fever with occasional pleuritic chest pain. In 
areas of high tuberculosis transmission, this form of disease is usually known to affect 
children.  After the initial infection, the lesion (Ghon focus) is usually peripheral and 
is accompanied by transient paratracheal or hilar lymphadenopathy. The expansion of 
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the tubercle into the lung parenchyma with associated lymphadenopathy results in 
Ghon complex.  
 
Progressive primary tuberculosis 
Primary pulmonary tuberculosis may progress rapidly to clinical illness in young 
children with immature cell mediated immunity and in persons with impaired cell 
mediated immunity (e.g., due to malnutrition or human immunodeficiency virus 
infection). The primary site can rapidly increase in size in severe cases, with central 
necrosis and development of cavity resulting in progressive primary tuberculosis. 
 
Post-primary (adult type) disease 
Also referred to as secondary or reactivation tuberculosis, it may result from 
reactivation of distant latent tuberculosis infection or recent infection (primary or re-
infection). It is usually localized to the apical and posterior segments of the upper 
lobe. The extent of lung parenchymal involvement varies greatly, from small 
infiltrates to extensive cavitary disease. 
 
SODIUM ABNORMALITIES 
 
The serum sodium concentration and thus serum osmolality are controlled closely by 
water homeostasis, which is mediated by thirst, arginine vasopressin, and the kidneys. 
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Water homeostasis disruption is manifested as an abnormality in the serum sodium 
concentration — hyponatremia or hypernatremia.  
 
HYPONATREMIA  
 
Hyponatremia is the most common electrolyte disorder encountered in clinical 
practice, with an incidence rate reported between 15-30%. True hyponatraemia is 
always associated with hypoosmolality. Hyponatremia is almost always the result of a 
combination of intake of free water combined with increased circulating AVP and/or 
increased renal sensitivity to AVP. 
 
Hyponatraemia is defined as a serum sodium concentration of < 135 mmol/l after the 
exclusion of ‘‘pseudo-hyponatraemia’’. In the latter, the non-aqueous components of 
plasma such as in hypertriglyceridaemia or hyperproteinaemia increases, resulting in a 
spuriously low sodium.  
 
It is important to recognize hyponatremia because of the potential morbidity 
associated with it and because it can be a marker of underlying disease. Although 
morbidity varies widely in severity, the disorder itself and errors in management can 
lead to serious complications.  
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ACUTE HYPONATREMIA 
 
Acute onset hyponatremia (< 48 hours) has severe symptoms as compared to chronic 
hyponatremia, where patients maybe asymptomatic or may have subtle symptoms like 
increased frequency of falls(25). 
 
The clinical manifestations of acute hyponatremia vary with severity with serious 
effects manifesting at lower sodium levels. The earliest findings, nausea and malaise, 
may be seen when the serum sodium concentration falls between 125 and 130 
mmol/L. Progressive central nervous system effects ranging from headache, lethargy, 
obtundation and eventually seizures, coma, and respiratory arrest can occur if the 
serum sodium concentration drops to between 115 and 120 mmol/L. Non-cardiogenic 
pulmonary edema leading to normocapneic respiratory failure has also been described. 
CHRONIC HYPONATREMIA 
 
The cerebral adaptation permits patients with chronic hyponatremia to appear to be 
asymptomatic despite a serum sodium concentration below 120 mmol/L. When 
symptoms do occur in patients with serum sodium concentrations at this level, they 
are relatively nonspecific.  
 
24 
 
Symptoms associated with chronic hyponatremia are - fatigue, nausea, dizziness, gait 
disturbance, forgetfulness, confusion, lethargy and muscle cramps. Seizures and coma 
are uncommon and often reflect an acute exacerbation of the hyponatremia. 
Symptomatic chronic hyponatremia is rarely associated with cerebral edema severe 
enough to cause herniation of the brain. 
 
ETIOLOGY AND PATHOPHYSIOLOGY 
 
Hyponatremia is classified into 3 types on the basis of volume status:  
 
1. Hypovolemic hyponatremia - where there is a decrease in total body water with 
greater decrease in sodium level. 
2. Euvolemic hyponatremia - where there is an increase in total body water with 
normal sodium level.  
3. Hypervolemic hyponatremia - where there is an increase in total body water 
compared with sodium(26). 
 
HYPOVOLEMIC HYPONATREMIA 
 
Hypovolemic hyponatremia is usually associated with cerebral salt wasting, diuretic 
use, gastro-intestinal loss, mineralocorticoid deficiency and third spacing. Patients 
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typically have signs and symptoms associated with volume depletion (e.g., 
tachycardia, vomiting, diarrhoea, elevated blood urea nitrogen–to-creatinine ratio). 
Urinary sodium level is usually less than 20 mEq/l (due to reabsorption by kidneys), 
unless the kidney is the site of sodium loss. If the patient is receiving diuretics, 
fractional excretion of sodium is often inaccurately elevated because of diuretic-
induced natriuresis. In these patients fractional excretion of urea can be utilized  
instead(27). 
 
Treatment of hypovolemic hyponatremia generally consists of volume repletion with 
isotonic (0.9%) saline, occasional use of salt tablets, and treatment of the underlying 
condition. 
 
 
EUVOLEMIC HYPONATREMIA 
 
 
Most common cause of euvolemic hyponatremia is SIADH, but it can also be caused 
by hypothyroidism and glucocorticoid deficiency. Euvolemia is diagnosed clinically 
by findings from the history and physical examination, low serum uric acid levels, a 
normal blood urea nitrogen–to-creatinine ratio, and spot urinary sodium greater than 
20 mEq/L.  Treatment generally consists of increased salt intake, fluid restriction and 
correcting the underlying cause. Fluid restriction should be limited to 500 mL less 
than the daily urinary volume(28).   
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HYPERVOLEMIC HYPONATREMIA 
 
 
Hypervolemic hyponatremia occurs when the kidneys cannot excrete water efficiently. 
In volume overload states, the effective arterial blood volume is decreased compared 
with venous volume, resulting in excess ADH secretion. The most common etiology 
of hypervolemic hyponatremia are congestive heart failure, liver cirrhosis, and chronic 
kidney failure. Treatment consists of correcting the underlying cause, sodium and 
fluid restriction, and diuretic therapy to increase excretion of solute-free water(28). 
 
 
 
SIADH 
 
The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) is the most 
frequent cause of hyponatremia (29). SIADH was first described in 1956 in two 
patients with bronchogenic carcinoma in whom a physiologic stimulus for the release 
of the antidiuretic hormone was lacking(30). The level of secretion of antidiuretic 
hormone was deemed inappropriate. Later, antidiuretic hormone in humans was found 
to be arginine vasopressin (AVP). 
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AVP is produced predominantly in magnocellular neurons in the supraoptic nuclei in 
the hypothalamus, subsequently transported down axon terminals through the 
supraoptic hypophyseal tract, and eventually stored in the posterior pituitary as 
inactive complexes with neurophysins(31). AVP is released quantally by exocytosis 
from secretory granules in response to osmotic and non-osmotic stimuli.  
 
AVP levels may not be elevated in all patients with the syndrome, hence the term 
syndrome of inappropriate anti-diuresis (SIAD) was proposed as an accurate 
description of this condition(25). Although inappropriate anti-diuresis is an essential 
feature of this syndrome, excessive water intake, driven by non-osmotic stimuli, is 
also required for hyponatremia to develop.  
 
 
DIAGNOSIS OF SIADH 
 
Decreased effective osmolality (< 275 mOsm per kilogram of water) with associated 
urine osmolality which exceeds 100 mOsm per kilogram of water suggests SIAD.  
The presence of clinical euvolemia is essential, because arginine vasopressin secretion 
is appropriate when effective arterial volume is depleted.  
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In the absence of a single laboratory test to confirm the diagnosis, the syndrome of 
inappropriate antidiuretic hormone secretion (SIADH) is best defined by the classic 
criteria introduced by Bartter and Schwartz in 1967(32). 
 
 
Hypouricemia, low blood urea nitrogen, and a urinary sodium level greater than 40 
mmol/l with normal dietary sodium intake in patients with hyponatremia suggest 
SIAD, but are not diagnostic. Measurement of the serum level of arginine vasopressin 
is not routinely recommended, urinary osmolality above 100 mOsm per kilogram of 
water is usually sufficient to indicate excess of circulating arginine vasopressin. 
Normal thyroid and adrenal function and absence of diuretic use adds to the 
diagnosis(25). 
 
SIADH has been reported in various conditions such as malignancies (lung, 
gastrointestinal, genitourinary), pulmonary diseases (infections like pneumonia, 
tuberculosis, aspergillosis; asthma, cystic fibrosis), disorders of the central nervous 
system (infections, stroke, tumours). Drugs are also implicated in causing SIADH, by 
stimulating the release of arginine vasopressin or potentiating its action (SSRI, TCA, 
carbamazepine, oxytocin)(33). 
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Tuberculosis can induce hyponatremia by various mechanisms including,  
infection of adrenal gland (adrenal insufficiency)(34,35), infection of hypothalamus or                 
pituitary gland(36,37), inappropriate ADH secretion via pulmonary infection(38,39) 
and secondary hyperaldosteronism(40).  Antidiuretic agents identical to arginine 
vasopressin have been demonstrated in tuberculous lung tissues(38). 
 
Hyponatremia is reported frequently in tuberculosis patients(41–43). Hypernatremia is 
not reported in any studies. 
 
In 1954, Doxiadis and Goldfinch, reviewed serum sodium levels of 19 patients 
diagnosed with tuberculosis. Approximately 19% of patients with active tuberculosis 
had hyponatremia(44).  
 
In 1965, Weiss and Katz, reviewed 4 patients with TB and hyponatremia and 
proposed SIADH to be the responsible for hyponatremia(45).   
 
In 1969, Chung and Hubbard, reviewed serum sodium levels of 522 newly diagnosed  
patients with tuberculosis. Approximately 11 % of patients with active TB  
were affected with hyponatremia, and the main cause of hyponatremia in  
these patients was thought to be dilutional(46).  
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In 1970, Vorherr et al. reported a case with pulmonary tuberculosis and hyponatremia 
and found antidiuretic agents in tuberculous lung tissues(47). 
 
In 1974, Schorn et al. reported two cases of PTB and an abnormal inappropriate 
antidiuretic hormone level as a justifier mechanism(48). 
 
In 1976, Cockcroft et al., reported a 74-year-old woman with miliary tuberculosis who 
presented with severe hyponatremia due to SIADH(49).  
 
In 1990, Hill et al. studied 22 patients with tuberculosis. Volume status was evaluated 
by urine sodium concentration, blood and urine urea nitrogen, and plasma renin 
activity. Endocrine, renal, and other recognized causes of SIADH were excluded. 
Plasma vasopressin, was detectable despite hypo-osmolality in 16 patients (72%)(50). 
  
In 2003, Nzerue et al. published a retrospective study of 168 patients with severe 
hyponatremia (< 115mmol/L) seen at a tertiary teaching hospital, in Atlanta. Mortality 
rate was high. 34 (20.2%) patients died. Sepsis, respiratory failure and the presence of 
symptoms predicted poor outcome in hospitalized patients with severe 
hyponatremia(51). 
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In 2006, Jafari et al. prospectively evaluated patients with a diagnosis of PTB who 
were admitted to the infectious wards.  Hyponatremia was detected in 51% patients. 
Mechanism of hyponatremia was not evaluated(52). 
 
HYPERNATREMIA 
 
As sodium contributes to effective osmolality (tonicity) being a functionally 
impermeable solute, it induces the movement of water across cell membranes. 
Therefore, hypernatremia invariably denotes hypertonic hyper osmolality and always 
causes cellular dehydration. The morbidity resulting from hypernatremia may be 
inconsequential, serious, or even life-threatening. Hypernatremia frequently develops 
as an iatrogenic condition in hospitalized patients, and inappropriate treatment results 
in some of its most serious complications(53).  
 
ETIOLOGY AND PATHOPHYSIOLOGY 
 
Hypernatremia can represent loss of water or gain of hypertonic sodium. Majority of 
the cases of hypernatremia are due to net water loss. It can occur in the absence of a 
sodium deficit (pure water loss) or in its presence (hypotonic fluid loss).  Hypertonic 
sodium gain is usually iatrogenic. Groups at highest risk are patients with altered 
mental status, intubated patients, infants, and elderly persons because sustained 
hypernatremia can occur only when thirst or access to water is impaired. 
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Hypernatremia in elderly persons is usually associated with infirmity or febrile 
illness(54). 
 
Signs and symptoms of hypernatremia are prominent when the increase in the serum 
sodium concentration is large or occurs rapidly (i.e., over a period of hours). The 
symptoms usually manifest as central nervous dysfunction. 
 
MANAGEMENT 
 
Proper treatment of hypernatremia requires management of the underlying cause and 
correcting the existing hypertonicity. Methods to address the underlying cause include 
controlling pyrexia, reducing gastrointestinal fluid losses, treating hyperglycemia and 
glucosuria, treating hypercalcemia and hypokalemia, withholding lactulose and 
diuretics and correcting the feeding preparation.  
 
Hypotonic fluids are preferred for correction and oral or feeding tube is preferred 
route for administering fluids. Intravenous route is used if not feasible. Fluids used 
include pure water, 5 percent dextrose, 0.2 percent sodium chloride, 0.45 percent 
sodium chloride. The speed of correction depends on the rapidity with which 
hypernatremia developed. In patients with hypernatremia that has developed over 
hours, rapid correction is appropriate without increasing risk of cerebral edema, 
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because accumulated electrolytes are rapidly extruded from brain cells. A slower rate 
of correction is appropriate in patients with hypernatremia of longer or unknown 
duration(55). 
 
CALCIUM ABNORMALITIES 
 
Calcium abnormalities have been variedly reported in studies related to tuberculosis, 
with majority of the studies reporting hypercalcemia and a few others reporting 
hypocalcemia as a major biochemical finding. The usual range of serum calcium in 
adults is between 2.15 and 2.60 mmol/L (8.6-10.4 mg/dL; 4.3-5.2 mEq/L).  
 
Approximately 45% of calcium in blood is bound to plasma proteins, particularly 
albumin, and about 10% is bound to anions such as citrate and phosphate. Ionised or 
free calcium (normal values 1.17-1.33 mmol/L) represents about 45% of total calcium. 
Although the ionised fraction of calcium is the one readily available for physiological 
processes, total serum calcium is usually measured in clinical practice. However, the 
total serum calcium may vary, when the serum protein concentration fluctuates, while 
ionised calcium remains stable.  
 
Total corrected serum calcium can be derived from the formula: total measured 
calcium concentration (mg/dL) + 0.8 (4−serum albumin concentration(mg/dL))(56).  
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Equilibrium constant of the albumin-ionised calcium complexes can be altered by 
variation in blood pH, with acidosis reducing the binding and alkalosis enhancing it. 
Measurement of ionised calcium is recommended, when major variation in serum 
protein levels or blood pH is suspected to determine the physiological serum calcium 
level(57).  
 
Parathyroid hormone (PTH), in association with vitamin D, is the main regulator of 
calcium concentration in serum. PTH increases resorption and delivery of calcium 
from the skeleton to the extracellular fluid. It also acts on the kidney to increase 
tubular reabsorption of calcium and stimulates the renal 1- - hydroxylase enzyme 
which is responsible for the 1-  -hydroxylation of 25-hydroxycholecalciferol 
[25(OH)D3] to 1,25-dihydroxycholecalciferol [1,25(OH)2D3]. The active form of 
vitamin D [1,25 (OH)2D3] increases the fractional absorption of calcium from the 
gut(58). 
 
HYPERCALCEMIA 
 
Hypercalcaemia is diagnosed when the concentration of serum calcium is 2 standard 
deviations above the mean of values found in people with normal calcium levels, in at 
least two samples at least one week apart over a period of three months. 
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The most common cause of hypercalcemia is primary hyperparathyroidism with an 
estimated prevalence of 1-7 cases per 1000 adults. It predominantly affects the older 
population (≥65 years) and women are affected two or three times more frequently 
than men(59). 
 
Other main etiologies of hypercalcemia include malignancy, drugs (thiazide, lithium), 
thyrotoxicosis and granulomatous diseases. Granulomatous disease in which 
hypercalcemia has been documented include sarcoidosis, berylliosis, histoplasmosis, 
coccidioidomycosis and candidiasis in addition to tuberculosis(60). Sarcoidosis is the 
most common granulomatous disease causing hypercalcemia.  
 
Hypercalcemia in association with high serum calcitriol (1,25-
dihydroxycholecalciferol [1,25(OH)2D3]) levels has been reported in 
tuberculosis(61,62). Dysregulated production of 1,25(OH)2D3 by activated 
macrophages trapped in pulmonary alveoli and granulomas are likely the source  of 
high calcitriol levels(63). In patients with pulmonary TB, T-lymphocytes (possibly 
CD8+ T-lymphocytes), and alveolar macrophages obtained by bronchoalveolar lavage 
have been shown to produce 1,25-dihydroxycholecalciferol [1,25(OH)2D3](64).  
 
The 1-alpha-hydroxylase activity in macrophages is activated by other mechanisms, 
such as gamma interferon or endotoxin, instead of parathyroid hormone(65). 
1,25(OH)2D3 produced by T-cells plays an important role in the immune response 
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against mycobacteria as it is an important component of cell-mediated immunity to 
tuberculosis. The produced vitamin D does not normally affect calcium metabolism, 
and has only a local effect in enhancing macrophages to kill mycobacteria. However, 
if large quantities of 1,25(OH)2D3 are produced, the subsequent spill over into the 
circulation results in hypercalcaemia(66). Increased intestinal absorption of calcium 
and possibly increased bone resorption due to elevated circulating concentrations of 
[1,25(OH)2D3] is thought to be responsible for this(67). 
 
Patients with hypercalcaemia often presents with polyuria, polydipsia, abdominal 
pain, vomiting, constipation and obtundation.  
 
The prevalence of hypercalcemia in patients with tuberculosis varies widely between 
countries in patients with active tuberculosis. This difference has been attributed to 
difference in vitamin D and calcium intake, difference in degree of exposure to 
sunlight and varying laboratory criteria for diagnosis of hypercalcemia(68).  
 
During exposure to sunlight, Ultraviolet B radiation converts 7-dehydrocholesterol to 
vitamin D3. Further hydroxylation occurs in liver and kidney respectively to the 
physiologically active form 1,25-dihydroxycholecalciferol [1,25(OH)2D3]. In tropical 
climates, where the amount of sun exposure is high, the concentration of vitamin D3 is 
increased(69).  Hence patients from tropics, where sunlight is plentiful have more 
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circulating vitamin D available for extra-renal synthesis of [1,25(OH)2D3] than others 
and may give rise to hypercalcaemia in the presence of tuberculosis(70). 
 
Calcium is complexed to albumin in serum, however only the free or ionized calcium 
is physiologically relevant(71). Hence. It is important that serum calcium be corrected 
for the serum albumin, or, ideally, to use serum ionized calcium as criteria for 
hypercalcemia(72).   
 
In 1979, Abbasi et al. reviewed retrospectively the incidence of hypercalcemia in 79 
consecutive patients admitted with diagnosis of active pulmonary tuberculosis in 
USA. 22 (28%) patients developed hypercalcemia during the course of illness. 
Hypercalcemia resolved with treatment in all the patients(73). 
 
In 1980, Kitrou et al. studied the prevalence of hypercalcemia in 50 consecutive 
patients admitted with diagnosis of active pulmonary tuberculosis in Greece. 24 (48%) 
patients were detected to have hypercalcemia at admission. Majority of the patients 
were asymptomatic, except for 2 patients(74). 
 
In 1981, Sharma studied the prevalence of hypercalcemia in 94 patients with 
tuberculosis in India. 16% patients had hypercalcemia(75).  
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In 1990, Lind et al. studied the prevalence of hypercalcemia in 67 patients and 
reported 25% prevalence.   
 
In 1993, Tan et al. studied the prevalence of hypercalcemia in 43 patients with 
tuberculosis in Malaysia. Only 1(2.3%) out of 43 patients had hypercalcemia. This 
was in stark contrast to previously reported incidence rates of hypercalcemia  
(25-50%)(76). 
 
In 1994, Chan et al. studied the prevalence of hypercalcemia in 34 patients with 
tuberculosis in China. 15% patients had hypercalcemia(77).  
 
In 1998, Liam et al. studied prospectively the incidence of hypercalcemia in 120 
consecutive patients with tuberculosis in Malaysia. Elevated calcium level was 
detected in 27.5 % of patients.  Only 12% of these patients showed symptoms of 
hypercalcemia(78). 
 
In 2001, Roussos et al. studied prospectively the incidence of hypercalcemia in 88 
consecutive patients admitted with active pulmonary tuberculosis in Greece. 22 (25%) 
patients were detected to have hypercalcemia.  Only 14% of these patients showed 
symptoms of hypercalcemia(79).  
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Besides the above mentioned retrospective and prospective cases series, there are 
numerous case reports of hypercalcemia with tuberculosis(60,80–85). 
 
HYPOCALCEMIA 
 
Hypocalcemia in tuberculosis is less reported as compared to hypercalcemia.  
Majority of the cases are attributed to impaired intestinal absorption of calcium, 
deficient intake of calcium, malnutrition and consequent hypoalbuminemia(86).  
 
Poor exposure to sunlight results in vitamin D deficiency. Vitamin D deficiency 
results in decreased intestinal absorption of calcium. In the event of disease, decreased 
physical activity experienced by the patient due to the rest advised and consequence 
less exposure to sunlight has been postulated be responsible for vitamin D deficiency 
and hence hypocalcemia. 
 
In 1990, Shirai et al. reported hypocalcemia in 69 (38%) out of 183 patients with 
pulmonary tuberculosis in Japan(87).   
 
In 1997, Ali-Gombe et al. reported hypocalcemia in 45 (44%) out of 102 patients with 
pulmonary tuberculosis in Nigeria(88).  
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In 2004, Ijaz et al, studied calcium abnormalities in 152 patients with pulmonary 
tuberculosis in Pakistan. 52 (38%) patients had hypocalcemia, while 7 (5%) patients 
had hypercalcemia(89).  
In 2014, Rohini et al, assessed calcium levels in 40 patients with tuberculosis before 
initiation of treatment. The average calcium level was 1.2-fold less than matched 
controls. The difference persisted at 2 months and disappeared at end of 6 months(90). 
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METHODOLOGY 
 
 
This was a cross-sectional study conducted at the Christian Medical College, a tertiary 
hospital in Vellore, Tamil Nadu over the years 2016-2017.  This aim was to calculate 
the prevalence of sodium and calcium abnormality in adults admitted with tuberculosis. 
The study  protocol was approved by the institutional review board with IRB Min No: 
9975 dated 02.03.2016. Scanned copy of IRB is in annexure number -----. Patients were 
recruited and data was collected from June 2016 to July 2017.  
The study was performed as a cross sectional study, which is observational in 
design.  The aim was to obtain a representative sample by taking a cross section of the 
population. All the measurements for a study participant were obtained at a single point 
in time, although recruitment took place across a period of time. Samples were taken 
randomly to minimize selection bias.  
The diagnosis of TB was based on one or more of the following criteria in the relevant 
tissue or specimen: first, a positive smear for acid-fast bacilli; second, a positive culture 
for Mycobacterium tuberculosis; third, a typical histology showing the central area of 
caseation necrosis with epithelioid granulomas with or without positive staining for 
acid-fast bacilli; fourth, typical imaging and clinical features suggestive of tuberculosis. 
The study included both newly diagnosed patients as well as patients who are already 
on treatment.  
Blood samples were collected at the point of enrolment into the study for measurement 
of sodium, calcium, albumin and serum osmolality by multichannel automated analyser. 
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On treatment naïve patients, baseline samples were collected prior to starting ATT. 
Information regarding the type of tuberculosis, treatment details (including duration), 
HIV status, co-morbid illnesses and outcome at discharge was documented.  
The collected data was entered in clinical research form (CRF). The clinical research 
form (CRF) was filled by the principal investigator. The copy of the CRF is in annexure. 
Data from the CRF were entered into the epidata v 3.1 data entry software and then 
exported to SPSS version 17, IBM Corporation for analysis. 
 
 
PATIENT POPULATION 
 
The study included all  adult patients  admitted with active tuberculosis in the general medicine 
ward of Christian Medical College, Vellore between July 2016 and July 2017.   
 
 
INCLUSION CRITERIA   
 
1. Age 16 years or older   
2. Patients admitted with diagnosis of tuberculosis, irrespective of whether the 
patient is on treatment or not 
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CASE DEFINITIONS 
 
A bacteriologically confirmed TB case is one from whom a biological specimen is 
positive by smear microscopy, culture or WHO-approved rapid diagnostics (such as 
Xpert MTB/RIF).  
 
A clinically diagnosed TB case is one who does not fulfil the criteria for bacteriological 
confirmation but has been diagnosed with active TB by a clinician or other medical 
practitioner who has decided to give the patient a full course of TB treatment. This 
definition includes cases diagnosed on the basis of X-ray abnormalities or suggestive 
histology and extrapulmonary cases without laboratory confirmation.  
 
Pulmonary tuberculosis (PTB) refers to any bacteriologically confirmed or clinically 
diagnosed case of TB involving the lung parenchyma or the tracheobronchial tree. 
Miliary TB is classified as pulmonary tuberculosis because there are lesions in the 
lungs.  
 
Extrapulmonary tuberculosis (EPTB) refers to any bacteriologically confirmed or 
clinically diagnosed case of TB involving organs other than the lungs, e.g. pleura, lymph 
nodes, abdomen, genitourinary tract, skin, joints and bones, meninges. 
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Disseminated TB is defined as tuberculous infection involving the blood stream, bone 
marrow, liver, or 2 or more non-contiguous sites, or miliary TB. 
 
 
EXCLUSION CRITERIA  
 
1. Age less than 16 years 
2. Women who are pregnant  
3. Multi drug resistant  tuberculosis 
 
 
SETTING 
 
This study was carried out in the general medical wards and intensive care unit of 
Christian Medical College and Hospital, a tertiary hospital in Vellore, Tamil Nadu. 
 
 
STUDY METHODS 
 
 
All patients admitted with a diagnosis of tuberculosis and fulfilling the inclusion criteria 
were enrolled after taking consent. The consent was taken directly from the patient. If 
the patient was not able to sign, thumb impression was taken. In case the patient could 
not give consent because of his general condition, consent was taken from the family 
and subsequently from the patient after recovery. 
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Two millilitres of blood was drawn using all standard safety precaution and analysed 
for sodium and calcium levels.  To allow for protein binding of calcium, measured 
total serum calcium concentration was corrected for serum albumin concentration. If 
hyponatremia was present, serum osmolality was measured and clinical volume status 
of the patient was documented. Urine spot sodium, random cortisol and TSH was 
measured to further characterize the cause of hyponatremia.  
 
CALCIUM CORRECTION: 
 
In patients with hypoalbuminemia the corrected calcium levels was estimated using 
the following formula  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
measured total serum calcium (mg/dL) + 0.8 (4−serum albumin (mg/dL)).  
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FLOW CHART 
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HYPONATREMIA ALGORITHM 
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STATISTICS 
 
 
SAMPLE SIZE CALCULATION 
 
 
After literature review of similar studies which employed similar strategy, the 
maximum proportion of patients with hyponatremia in tuberculosis was 0.51 (P) and 
hypercalcemia in tuberculosis was 0.48. It is known that the true rate is unlikely to 
exceed 50%. We wanted to estimate the prevalence to within 10 percentage points of 
the true value, with 95% confidence.  
 
 
Anticipated population proportion (p) 0.5 
Confidence Interval (C.I) 95% 
Z score for 95% C.I. 1.96 
Absolute precision ( ) (40 – 60 %)  10% 
 
 
 
 
The sample size (n) calculated with p = 0.5 and d = 0.1 was 100 with 95% confidence 
interval. 
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STATISTICAL ANALYSIS  
 
 
Data from the CRF was entered into epidata v 3.1 data entry software and then exported 
to SPSS version 17, IBM Corporation for analysis. Pearson's chi-square test was used 
to discover if there is a relationship between two categorical variables. All analysis was 
performed by a biostatistician. 
 
 
              
FUNDING AND APPROVAL 
 
The study protocol was approved by the institutional review board with IRB Min No: 
9975 dated 02.03.2016 and the funding was provided by the FLUID grant of the 
institutional review board.  
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RESULTS 
 
 
STROBE figure 
 
 
 
 
 
 
 
All patients 
admitted in 
medical wards with 
diagnosis of TB
110 patients are 
screened
103 eligible
100 recruited for 
study
Ineligible for study (n=7) 
 MDR TB (n=4) 
 Pregnant (n=2) 
 Did not give consent (n=1) 
Excluded (n=3) 
 Diagnosis revised (n=3) 
51 
 
BASELINE CHARACTERISTICS 
 
 
 
Median age of patients was 38.5. 47% were females. 23% patients were diabetic and 
12% were hypertensive.  92% of patients were treatment naïve at the time of 
assessment of electrolyte status. 23% of the patients were diabetic and 12% were 
hypertensive. 2% of patients were seropositive.  
 
 
Variable n = 100 
Age, median years (range)  38.5 
Gender, n (%) 
Male 
Female 
 
53 
47 
Treatment status, N (%) 
on 
off 
 
 
 
8 
92 
Average treatment duration (days) 57.5 
Diabetes mellitus 23 
Hypertension 12 
Seropositive 2 
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AGE DISTRIBUTION 
 
 
     
 
Figure 1 Age distribution 
 
 
 N Minimum Maximum Mean Std. Deviation 
Age of patient 100 16 75 38.57 16.968 
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Figure 2 Age stratification 
 
 
 
  
Age Frequency Percent Valid Percent 
Cumulative 
Percent 
 16-29 43 43.0 43.0 43.0 
30-49 27 27.0 27.0 70.0 
50-75 30 30.0 30.0 100.0 
Total 100 100.0 100.0  
 
 
 
 
 
43
27 30
100
Age 16-29 30-49 50-75 Total
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GENDER 
 
 
 
  Frequency Percent Valid Percent Cumulative Percent 
 Male 53 53.0 53.0 53.0 
Female 47 47.0 47.0 100.0 
Total 100 100.0 100.0  
 
 
 
 
TREATMENT STATUS AT RECRUITMENT 
 
 
 
  
Frequency Percent Valid Percent Cumulative Percent 
 Treatment naive 92 92.0 92.0 92.0 
On 8 8.0 8.0 100.0 
Total 100 100.0 100.0  
 
 
 
8 (8%) patients were on treatment for tuberculosis at the time of recruitment with 
mean duration of treatment of 57.5 days. 
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Figure 3 treatment duration 
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N Valid 8 
Missing 92 
Median 60.00 
Minimum 10 
Maximum 120 
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COMORBID ILLNESSES 
 
 
HIV status 
  
Frequency Percent Valid Percent 
Cumulative 
Percent 
 positive 2 2.0 2.0 2.0 
negative 98 98.0 98.0 100.0 
Total 100 100.0 100.0  
 
 
 
Diabetes 
  
Frequency Percent Valid Percent 
Cumulative 
Percent 
 yes 23 23.0 23.0 23.0 
no 77 77.0 77.0 100.0 
Total 100 100.0 100.0  
 
 
Hypertension 
  
Frequency Percent Valid Percent 
Cumulative 
Percent 
 yes 12 12.0 12.0 12.0 
no 88 88.0 88.0 100.0 
Total 100 100.0 100.0  
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TYPE OF TUBERCULOSIS 
 
 
 
 
Figure 4 type of tuberculosis 
 
 
 
  
Frequency Percent Valid Percent 
Cumulative 
Percent 
 pulmonary 20 20.0 20.0 20.0 
CNS tuberculosis 32 32.0 32.0 52.0 
extrapulmonary 12 12.0 12.0 64.0 
disseminated 36 36.0 36.0 100.0 
Total 100 100.0 100.0  
 
 
20
32
12
36
100
pulmonary CNS tuberculosis extrapulmonary disseminated Total
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SODIUM ABNORMALITY 
 
 
 
Hyponatremia was detected in 43% of patients.  
 
 
 
Figure 5 Sodium levels 
 
 
 
 
  
Frequency Percent Valid Percent 
Cumulative 
Percent 
 hyponatremia 43 43.0 43.0 43.0 
normal 57 57.0 57.0 100.0 
Total 100 100.0 100.0  
 
 
43
57
100
HYPONATREMIA NORMAL TOTAL
Sodium levels
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ETIOLOGY OF HYPONATREMIA 
 
 
Distribution  
 
The predominant mechanism of hyponatremia was syndrome of inappropriate anti-
diuretic hormone secretion (SIADH), which was present in 28 (65%) of cases with 
hyponatremia. Hypovolemic hyponatremia was present in 6 (14%) of cases. 
Hypervolemic hyponatremia was present in 5 (11%) of cases. There were two cases 
with hypocortisolemia and one case each with hypothyroidism and 
pseudohyponatremia. 
 
   
        
           Figure 6 Etiology of hyponatremia 
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  Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
SIADH 28 28 65.1 65.1 
Euvolemic (other)* 3 3 7 72.1 
Hypovolemic 6 6 14 86 
Hypervolemic 5 5 11.6 97.7 
Pseudohyponatremia 1 1 2.3 100 
Total 43 43 100   
Normal  57 57     
Sample size 100 100     
 
* hypocortisolemia/hypothyroidism 
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STATISTICAL ANALYSIS OF SODIUM LEVELS 
 
Age 
The samples were stratified into two age groups. The prevalence of hyponatremia was 
slightly higher in the older (> 40) age group (45.7% vs. 40.7%). However, the 
difference between age groups were not statistically significant (p=.235). 
 
.  
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Gender 
The samples were stratified by gender. A higher percentage (50.9%) of male patients 
presented with hyponatremia, as compared to female patients (34%) . The difference 
between age groups approached statistical significance, but were still > 0.05 (p=.088). 
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Diabetes and Hypertension 
The samples were stratified by comorbid illnesses (diabetes and hypertension). 23% of 
the patients were diabetic and 12% were hypertensive. There wasn’t any statistical 
significance (p=0.594 and 0.253, respectively) between the presence of comorbid 
illnesses and development of hyponatremia.  
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Treatment status 
 
The samples were stratified by whether the patient was on treatment for tuberculosis 
at the time of recruitment. 8% of patients were on treatment for tuberculosis at the 
time of recruitment with mean duration of treatment of 57.5 days. There wasn’t any 
statistical significance (p=0.722) between the group which was on treatment and the 
treatment naïve group in relation to development of hyponatremia.  
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DISTRIBUTION OF HYPONATREMIA ACROSS TYPES OF TUBERCULOSIS 
 
 
50% of cases of pulmonary tuberculosis had hyponatremia on admission. 47% of 
cases of central nervous system and disseminated tuberculosis presented with 
hyponatremia. Hyponatremia was seen only in 1 case of extrapulmonary tuberculosis. 
 
 
Figure 7 Hyponatremia across types of tuberculosis 
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 n hyponatremia p value 
Pulmonary 20 10 (50%) 0.0162 
CNS tuberculosis 32 15 (47%) 0.0178 
Extrapulmonary 12 1   (03%)  
Disseminated 36 17 (47%) 0.0159 
 100 43  
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The lower prevalence rate of hyponatremia in extrapulmonary tuberculosis (3%) was 
statistically significant when compared to pulmonary (50%), central nervous system 
(47%) and disseminated tuberculosis (47%). 
 
 
DISTRIBUTION OF SIADH ACROSS TYPES OF TUBERCULOSIS 
 
 
Out of 43% cases of hyponatremia, 28% were attributed to SIADH. 80% of cases of 
CNS tuberculosis and 70% cases of pulmonary tuberculosis had SIADH as 
predominant mechanism of hyponatremia. SIADH was responsible for 53% of cases 
of hyponatremia in disseminated tuberculosis.  
 
 
Figure 8 SIADH across types of tuberculosis 
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 hyponatremia SIADH 
Pulmonary 10 07 (70%) 
CNS tuberculosis 15 12 (80%) 
Extrapulmonary 1 0    
Disseminated 17 09 (53%) 
 43 28 
 
The difference between pulmonary, CNS tuberculosis and disseminated tuberculosis 
were not statistically significant. 
 p value 
Pulmonary vs. CNS tuberculosis 0.653 
Pulmonary vs. disseminated 0.448 
CNS tuberculosis vs. disseminated 0.147 
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CALCIUM ABNORMALITY 
 
 
Hypercalcemia was detected in 4 (4%) of patients. Hypocalcemia was detected in 1 
(1%) patients.   
 
          
Figure 9 Calcium levels 
 
Calcium status 
  
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid hypocalcemia 1 1.0 1.0 1.0 
normal 95 95.0 95.0 96.0 
hypercalcemia 4 4.0 4.0 100.0 
Total 100 100.0 100.0  
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Calcium levels
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STATISTICAL ANALYSIS OF CALCIUM LEVELS 
 
Age 
 
The samples were stratified into two age groups. 3 (75%) out of 4 cases of 
hypercalcemia was seen in the younger (<40) age group. The difference of prevalence 
of hypercalcemia between the age groups was not statistically significant (p=0.354). 
The only case of hypocalcemia was also seen in the younger (<40) age group. The 
difference of prevalence of hypocalcemia between the age groups was not statistically 
significant (p=0.389). 
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Gender 
 
The samples were stratified by gender. 3 (75%) out of 4 cases of hypercalcemia were 
males. The prevalence of hypercalcemia was not statistically different between males 
and females (p=0.289). The only case of hypocalcemia was a female patient. The 
prevalence of hypocalcemia was not statistically different between males and females 
(p=0.359). 
 
 
 
                                    
Diabetes and Hypertension 
 
The samples were stratified by comorbid illnesses (diabetes and hypertension). 23% of 
the patients were diabetic and 12% were hypertensive.  
3 (75%) out of 4 cases of hypercalcemia were non-diabetic. The only case of 
hypocalcemia was a non-diabetic. There wasn’t any statistically significant difference 
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between the presence of diabetes and development of hypercalcemia (p=0.932) or 
hypocalcemia (p=0.583). 
 
 
All cases of hypercalcemia were non-hypertensive. The only case of hypocalcemia 
was a non-hypertensive. There wasn’t any statistically significant difference between 
the presence of hypertension and development of hypercalcemia (p=0.453) or 
hypocalcemia (p=0.715). 
 
 
 
 
 
 
 
73 
 
Treatment status 
 
The samples were stratified by whether the patient was on treatment for tuberculosis 
at the time of recruitment. 8% of patients were on treatment for tuberculosis at the 
time of recruitment with mean duration of treatment of 57.5 days. 3 (75%) out of 4 
cases of hypercalcemia were treatment naïve. The only case of hypocalcemia was 
treatment naïve. There wasn’t any statistically significance difference between the 
treatment naïve group and the group which was on treatment in relation to 
development of hypercalcemia (p=0.205) or hypocalcemia (p=0.766).  
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OUTCOME OF ILLNESS 
 
 
Mortality rate was 5%.  
 
 
                  
  Figure 10 Outcome at discharge 
 
 
Outcome at discharge 
  
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid alive 95 95.0 95.0 95.0 
dead 5 5.0 5.0 100.0 
Total 100 100.0 100.0  
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OUTCOME IN RELATION TO THE SODIUM STATUS 
 
4 (9.3%) patients with hyponatremia expired during the course of illness.  The 
mortality rate among patients with hyponatremia was slightly higher (9.3% vs. 1.8%) 
than those patients without hyponatremia. The difference was not statistically 
significant (p=0.162). 
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OUTCOME IN RELATION TO THE CALCIUM STATUS 
 
 
1 (25%) patient with hypercalcemia expired during the course of illness.  The 
mortality rate among patients with hypercalcemia (25%) as compared to normal 
calcium level (4.2%) was not statistically significant (p=0.482).  This was due to the 
low number of patients with hypercalcemia (4%) as compared to normal calcium 
levels. 
There was no mortality in the hypocalcemia group. 
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DISCUSSION 
 
 
The primary objective of the study was to calculate the prevalence of sodium and 
calcium abnormality in adult patients admitted with diagnosis of tuberculosis. 
  
The prevalence of hyponatremia detected in the study was 43%. This is much higher 
than the prevalence rates detected in studies done in USA (11%)(45) and Greece 
(18%)(44). However, the rate was comparable with the study done by Jafari et al. in 
Iran (51%)(52). Tuberculosis can induce hyponatremia by various mechanisms 
including, infection of adrenal gland (adrenal insufficiency)(34,35), infection of 
hypothalamus or pituitary gland(36,37), inappropriate ADH secretion via pulmonary 
infection(38,39) and secondary hyperaldosteronism(40).  50% of cases of pulmonary 
tuberculosis had hyponatremia on admission. 47% of cases of central nervous system 
and disseminated tuberculosis presented with hyponatremia. Hyponatremia was seen 
only in 1 case of extrapulmonary tuberculosis. This is consistent with previous studies 
were pulmonary and CNS involvement predisposed to hyponatremia.  Hypernatremia 
was not detected in any patients. 
 
The data was statistically analysed. There was no significant difference in 
hyponatremia when the samples were stratified by age, gender, co-morbid illnesses. 
The samples were also analysed to see of the initiation of treatment made any 
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significant differences in the prevalence of hyponatremia, however the results were 
non-significant. 
 
The prevalence of hypercalcemia detected in the study was 4%. This is much lower 
than the prevalence rate detected in a study done previously in India (16%)(75). 
However, the rate was comparable with a study done by Tan et al. in Malaysia 
(1%)(76). The highest prevalence rate was detected in a study done by Kitrou et al. in 
Greece(48%) (74).  Hypercalcemia in association with high serum calcitriol (1,25-
dihydroxycholecalciferol [1,25(OH)2D3]) levels has been reported in 
tuberculosis(61,62). Dysregulated production of 1,25(OH)2D3 by activated 
macrophages trapped in pulmonary alveoli and granulomas are likely the source  of 
high calcitriol levels(63). In patients with pulmonary TB, T-lymphocytes and alveolar 
macrophages obtained by bronchoalveolar lavage have been shown to produce 1,25-
dihydroxycholecalciferol [1,25(OH)2D3](64).  
 
The prevalence of hypocalcemia detected in the study was 1%. This is much lower 
than the prevalence detected in previous studies (38-44%)(87–89). Majority of the 
cases of hypocalcemia in tuberculosis are attributed to impaired intestinal absorption 
of calcium, deficient intake of calcium, malnutrition and consequent 
hypoalbuminemia(86).  Poor exposure to sunlight results in vitamin D deficiency, 
which results in decreased intestinal absorption of calcium. In the event of disease, 
decreased physical activity experienced by the patient due to the rest advised and 
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consequence less exposure to sunlight has been postulated be responsible for vitamin 
D deficiency and hence hypocalcemia. 
 
The data was statistically analysed. There was no significant difference in 
hypercalcemia or hypocalcemia when the samples were stratified by age, gender, co-
morbid illnesses. The lower prevalence rate of hyponatremia in extrapulmonary 
tuberculosis was statistically significant when compared to pulmonary, central 
nervous system and disseminated tuberculosis. 
 
There were three secondary objectives  
 
 To assess the mechanism of hyponatremia. 
 
The predominant mechanism of hyponatremia in our study was syndrome of 
inappropriate anti-diuretic hormone secretion (SIADH), which was present in 65% of 
cases with hyponatremia. Hypovolemic hyponatremia was present in 14% of cases. 
Hypervolemic hyponatremia was present in 11% of cases. There were two cases with 
hypocortisolemia and one case each with hypothyroidism and pseudohyponatremia.  
 
There are only a few studies which have been done previously which evaluated the 
etiology of hyponatremia concurrently while studying the prevalence rates. In one of 
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the first reports, Weiss et al., in 1965, reported hyponatremia resulting from SIADH in 
4 patients with pulmonary tuberculosis. Singh et al., in 1994, reported hyponatremia 
in 65% of the 22 patients admitted with tubercular meningitis.  All patients had 
SIADH.  The findings in our study was consistent with these studies with SIADH 
being the main mechanism of hyponatremia.  
 
 To assess relationship between type of tuberculosis and electrolyte abnormality 
 
Hyponatremia was attributed to SIADH in 70% and 80% cases of pulmonary and 
CNS tuberculosis, respectively. There were no cases of SIADH in extrapulmonary 
tuberculosis. This is consistent with the data reported in previous studies.  The 
prevalence of SIADH was not statistically significant among pulmonary, central 
nervous system and disseminated tuberculosis. 
 
Hypercalcemia was seen in four cases. Three of those cases were disseminated 
tuberculosis. The only case of hyponatremia detected in the study was also 
disseminated tuberculosis. The results were not statistically significant among 
pulmonary, central nervous system, extrapulmonary and disseminated tuberculosis. 
 
 To assess outcome at discharge in relation to electrolyte abnormality 
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Five of the recruited patients expired during the course of illness (one case of 
pulmonary tuberculosis and four cases of disseminated tuberculosis). Four of these 
patients had hyponatremia and one had hypercalcemia. These differences were not 
statistically significant. 
 
LIMITATIONS 
 
The study had the following limitations. As the exposure and outcome were assessed 
simultaneously, temporal relationship between them cannot be established. As 
measurements were obtained at a single point in time, trends in outcome could not be 
monitored over time. As the study is not longitudinal by design, new cases of 
hyponatremia which developed over time could not be measured..   
 
 
CONCLUSIONS 
 
 
 
The primary objective of the study was to calculate the prevalence of sodium and 
calcium abnormality in adult patients admitted with diagnosis of tuberculosis. 
Hyponatremia was detected in 43% of patients. Hypernatremia was not detected in 
any patients. Hypercalcemia was detected in 4% of patients. Hypocalcemia was 
detected in 1% patients.  
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The predominant mechanism of hyponatremia was syndrome of inappropriate anti-
diuretic hormone secretion (SIADH), which was present in 65% of cases with 
hyponatremia. SIADH was responsible for 70% and 80% of cases of hyponatremia in 
pulmonary and CNS tuberculosis respectively.  
 
Early detection and treatment of underlying electrolyte abnormality can potentially 
reduce mortality and morbidity associated with tuberculosis and reduce duration of 
hospitalization. Further research into the prevalence of potassium, magnesium and 
chloride abnormalities can add to the lacunae of knowledge. Longitudinal studies can 
be used to assess the incidence of electrolyte abnormality which develop over the 
course of illness.  
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ANNEXURE 6: EXTRA TABLES/FIGURES 
 
 
 
Serum osmolality 
  
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid hypoosmolar 42 42.0 97.7 97.7 
isoosmolar 1 1.0 2.3 100.0 
Total 43 43.0 100.0  
Missing  57 57.0   
Total 100 100.0   
 
 
 
Volume status 
  
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid hypovolemic 6 6.0 14.3 14.3 
euvolemic 31 31.0 73.8 88.1 
hypervolemic 5 5.0 11.9 100.0 
Total 42 42.0 100.0  
Missing  58 58.0   
Total 100 100.0   
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Urine spot sodium 
  
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid less than 20 6 6.0 14.3 14.3 
more than 20 36 36.0 85.7 100.0 
Total 42 42.0 100.0  
Missing System 58 58.0   
Total 100 100.0   
 
 
 
 
Vitamin D levels 
  
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid normal 1 1.0 1.0 1.0 
insufficient 15 15.0 15.0 16.0 
not known 84 84.0 84.0 100.0 
Total 100 100.0 100.0  
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ANNEXURE 7: THESIS DATA 
 
Section-1 
ID HID AGE SEX Ty 
Tb 
Rx  Rx HIV  DM HTN NA SNA VNA 
1 692462b 18 1 1 0   2 2 2 1 1 2 
2 677690g 58 1 1 0   2 1 1 1 1 2 
3 531959g 52 1 1 1 60 1 1 2 1 2   
4 519716f 54 1 1 0   2 1 1 1 1 2 
5 530269g 45 1 4 1 70 1 2 2 1 1 2 
6 736267g 20 1 1 0   2 1 2 2     
7 532939g 27 1 2 0   2 2 2 1 1 2 
8 534025g 32 2 2 0   2 1 2 2     
9 530652g 23 2 4 1 20 2 2 2 2     
10 534274g 21 2 2 0   2 2 2 1 1 2 
11 534035g 21 2 2 0   2 2 2 1 1 2 
12 659195g 31 2 2 1 60 2 2 2 1 1 1 
13 530372g 24 2 1 0   2 2 2 2     
14 530905g 21 2 4 1 10 2 2 2 2     
15 786470g 38 1 1 0   2 2 2 1 1 1 
16 524923g 18 2 2 0   2 2 2 2     
17 540957g 69 1 1 0   2 1 2 1 1 2 
18 704847c 73 2 1 0   2 1 2 1 1 2 
19 559294d 61 1 2 0   2 1 2 2     
20 733292g 28 1 4 0   2 2 2 1 1 2 
21 888703f 66 2 4 0   2 2 2 2     
22 743548g 25 2 3 0   2 2 2 2     
23 514248g 21 2 4 1 120 2 2 2 2     
24 192275d 35 1 4 0   2 2 2 2     
25 450006c 63 1 1 0   2 1 1 2     
26 548421g 16 1 4 0   2 2 2 1 1 2 
27 604447g 52 1 1 0   2 2 2 2     
28 557138g 56 1 2 1 60 2 1 1 1 1 2 
29 853023g 48 2 2 0   2 2 2 2     
30 246567f 44 1 2 0   2 1 2 2     
31 778167g 18 2 4 0   2 2 2 1 1 2 
32 559110g 25 2 2 0   2 2 2 2     
33 872916g 44 1 1 0   2 1 2 2     
34 532962g 19 1 3 0   2 2 2 2     
35 349855a 29 1 3 0   2 2 2 2     
36 546063g 42 1 4 0   2 1 2 1 1 2 
37 408598g 26 2 4 0   2 2 2 2     
38 561068g 30 2 2 0   2 2 2 1 1 2 
39 804834g 37 2 4 0   2 2 2 1 1 1 
40 777358c 42 1 4 0   2 2 1 1 1 3 
41 825966g 28 2 4 0   2 2 2 2     
42 546665g 19 1 2 1 60 2 2 2 2     
43 547882g 31 1 2 0   2 2 2 1 1 2 
44 524275f 56 1 2 0   2 1 2 1 1 2 
45 750168g 19 2 4 0   2 2 2 2     
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46 746187g 25 1 4 0   2 2 2 2     
47 532031g 27 1 2 0   2 2 2 1 1 2 
48 193953b 74 1 3 0   2 1 1 2     
49 527689g 39 2 2 0   2 2 2 1 1 2 
50 530276g 25 1 4 0   2 2 2 1 1 1 
51 697024g 69 1 3 0   2 1 1 2     
52 530280g 53 1 1 0   2 1 2 1 1 3 
53 715053g 42 2 1 0   2 2 2 2     
54 524109g 70 2 2 0   2 2 2 2     
55 523840g 27 2 4 0   2 2 2 1 1 2 
56 526482g 67 1 4 0   2 2 2 1 1 2 
57 527241g 19 1 2 0   2 2 2 1 1 1 
58 527050g 66 1 3 0   2 1 2 2     
59 527199g 23 1 2 0   2 2 2 2     
60 641414g 49 1 4 0   2 2 1 1 1 3 
61 520456g 17 2 4 0   2 2 2 2     
62 521230g 56 2 4 0   2 1 1 2     
63 948855f 23 2 2 0   2 2 2 1 1 2 
64 523562g 27 2 4 0   2 2 2 2     
65 355943g 52 1 3 0   2 2 2 2     
66 512271g 52 1 2 0   2 2 2 1 1 2 
67 514297g 40 1 2 0   2 2 2 1 1 2 
68 634996g 22 2 3 0   2 2 2 2     
69 614041g 23 1 4 0   2 2 2 2     
70 489734g 22 2 2 0   2 2 2 2     
71 510896g 55 2 3 0   2 1 1 1 1 3 
72 511175g 46 1 1 0   2 2 2 1 1 2 
73 512082g 41 2 1 0   2 2 2 2     
74 487726g 16 1 4 0   2 2 2 2     
75 503287g 50 2 4 0   2 1 2 1 1 3 
76 505653g 42 2 4 0   2 2 2 1 1 1 
77 499139g 22 2 4 0   2 2 2 2     
78 771826g 20 1 2 0   2 2 2 2     
79 712991d 27 2 4 0   2 2 2 1 1 2 
80 773419g 65 1 4 0   2 2 2 1 1 2 
81 773470g 35 1 1 0   2 2 1 1 1 2 
82 455635f 24 1 2 0   2 2 2 1 1 2 
83 543979g 50 2 3 0   2 2 2 2     
84 557020g 32 2 2 0   2 2 2 2     
85 819870g 57 1 4 0   2 2 2 2     
86 864505g 44 1 3 0   2 2 2 2     
87 656654g 43 2 2 0   2 2 2 2     
88 559867g 35 2 4 0   2 2 2 2     
89 549769g 22 2 4 0   2 2 2 1 1 2 
90 557018g 25 2 2 0   2 2 2 2     
91 558027g 28 2 2 0   2 2 2 2     
92 557820g 46 2 4 0   2 2 2 1 1 2 
93 546627g 19 2 1 0   2 2 2 2     
94 542844g 21 1 2 0   2 2 2 2     
95 544485g 75 2 3 0   2 2 2 2     
96 447268f 40 1 2 0   2 2 2 2     
97 546931g 68 1 4 0   2 1 2 2     
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98 547378g 61 1 1 0   2 2 2 2     
99 764241g 59 2 4 0   2 1 1 2     
100 545993g 55 1 1 0   2 2 2 2     
 
Section-2 
ID THY CORT UNA CHF NF CR EXR RF DI ENa  Ca VD OUT 
1 2 2 2         2 2 1 2 3 1 
2 2 2 2         2 2 1 2 3 1 
3                   5 2 3 1 
4 2 2 2         1 2 1 2 3 1 
5 2 2 2         2 2 1 2 3 1 
6                     2 3 1 
7 9 9 2         2 2 1 2 3 1 
8                     2 3 1 
9                     2 3 1 
10 2 2 2         2 2 1 2 3 1 
11 2 2 2         2 2 1 2 3 1 
12 2 2 2         2 2 3 2 2 1 
13                     2 3 1 
14                     2 3 1 
15     1 2 2 2 1 2 2 3 2 3 1 
16                     2 3 1 
17 2 2 2         2 2 1 2 2 1 
18 2 2 2         2 2 1 2 3 2 
19                     2 3 1 
20 2 1 2         2 2 2 2 3 1 
21                     2 3 1 
22                     2 3 1 
23                     3 2 2 
24                     2 3 1 
25                     2 2 1 
26 2 2 2         2 2 1 2 2 1 
27                     2 3 1 
28 2 2 2         2 2 1 2 2 1 
29                     2 3 1 
30                     2 3 1 
31 2 2 2         2 2 1 2 3 1 
32                     2 3 1 
33                     2 3 1 
34                     2 3 1 
35                     2 3 1 
36 2 2 2         2 2 1 2 3 1 
37                     2 3 1 
38 2 2 2         2 2 1 2 3 1 
39     1 2 2 2 1 2 2 3 2 3 2 
40     2         1 2 4 2 3 2 
41                     2 3 1 
42                     2 3 1 
43 2 2 2         2 2 1 2 3 1 
44 2 2 2         2 2 1 2 3 1 
45                     2 3 1 
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46                     3 2 1 
47 2 2 2         2 2 1 2 3 1 
48                     2 3 1 
49 2 2 2         2 2 1 2 3 1 
50     1 2 2 2 1 2 2 3 2 3 2 
51                     2 3 1 
52     2         1 2 4 2 2 1 
53                     2 3 1 
54                     2 3 1 
55 2 2 2         2 2 1 2 3 1 
56 1 2 2         2 2 2 2 3 1 
57     1 2 2 2 1 2 2 3 2 3 1 
58                     3 1 1 
59                     2 3 1 
60     1 2 2 2 2 2 2 4 2 3 1 
61                     2 3 1 
62                     2 3 1 
63 1 2 2         2 2 2 2 3 1 
64                     2 3 1 
65                     2 3 1 
66 2 2 2         2 2 1 2 2 1 
67 2 2 2         2 2 1 2 3 1 
68                     2 2 1 
69                     2 3 1 
70                     2 3 1 
71     2         1 2 4 2 3 1 
72 2 2 2         2 2 1 2 3 1 
73                     2 3 1 
74                     3 2 1 
75     1 2 2 2 2 2 2 4 2 3 1 
76     2         2 2 3 2 3 1 
77                     1 2 1 
78                     2 3 1 
79 2 2 2         2 2 1 2 3 1 
80 2 2 2         2 2 1 2 3 1 
81 2 2 2         2 2 1 2 3 1 
82 2 2 2         2 2 1 2 3 1 
83                     2 3 1 
84                     2 2 1 
85                     2 2 1 
86                     2 3 1 
87                     2 2 1 
88                     2 3 1 
89 2 2 2         2 2 1 2 3 1 
90                     2 3 1 
91                     2 3 1 
92 2 2 2         2 2 1 2 3 1 
93                     2 3 1 
94                     2 3 1 
95                     2 3 1 
96                     2 3 1 
97                     2 3 1 
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98                     2 3 1 
99                     2 3 1 
100                     2 3 1 
 
